M-7583

N/A

Report date: 2023/05/05 17:37:10
NME

Base Information

Drug NameM-7583
Drug Alias NameM7583M-7583
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsLymphoma, Mantle-CellLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUkrainePoland +[8] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMerck & Co Inc
China Registration ClassN/A

Develop Information

Active CompaniesTelios Pharmaceuticals
Inactive CompaniesMerck KGaA, Darmstadt, Germany
Active IndicationsLymphoma, Mantle-CellLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A